BioSpace News Archive

GC LabTech, a subsidiary of GC Biopharma of South Korea, and a CAP & ISO accredited, FDA-registered specialty laboratory with life-saving plasma tests, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.

Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies.

This month, North Carolina State University and TruDiagnostic take the next step in their investigation into the human imprintome with an exclusive license agreement to any diagnostic techniques utilizing imprintome control regions.

ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure in patients chronically infected with Hepatitis B, announced today that two abstracts were accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting, to be held in Washington, DC, USA, November 4 – 8, 2022.

V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double-blinded, sham-controlled, multi-center pivotal clinical trial.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fiscal year 2023 second quarter after the market closes on Monday, November 7, 2022.

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.